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lioblastoma (GBM) is the most common
type of primary malignant brain cancer.1,2
Approximately 10,000 new cases of GBM
are diagnosed in the United States each year, and the
estimated worldwide incidence rate is 3.5 per
100,000 people.3 Median overall survival (OS) for
patients with newly diagnosed GBM is only 12 to 18
months, with standard therapy consisting of surgical
resection together with adjuvant chemotherapy
(temozolomide) and radiotherapy.1,3–6 Of patients
with GBM, 90% to 95% die within 5 years of
diagnosis.1,2,5 Nearly all patients with GBM experi-
ence disease progression despite aggressive first-line
therapy, with a median time to progression of 6 to
11 months.1,4,7 Treatment options for GBM at the
time of recurrence are limited, and there is no widely
accepted standard treatment.7–9 The NovoTTF-100A
System (Novocure Ltd., Haifa, Israel) is an approvedology, Vol 41, No 5, Suppl 6, October 2014, pp S14-S24
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GBM.10 It utilizes low-intensity, intermediate-fre-
quency alternating electric fields, or tumor-treating
fields (TTFields), to selectively kill or arrest the
growth of rapidly dividing GBM cells by inhibiting
the proper formation of the mitotic spindle and by
causing rapid membrane breakdown during cytoki-
nesis.10–13 TTFields are delivered, in conjunction
with magnetic resonance imaging (MRI) guidance,
via noninvasive transducer arrays attached to the
patient’s scalp. Recommended usage isZ18 hours
per day in each 4-week treatment cycle.14 A phase III
trial comparing NovoTTF monotherapy with chemo-
therapy according to physician’s choice in patients
with recurrent GBM reported similar median OS in
the intention-to-treat (ITT) population, 6.6 versus
6.0 months respectively (hazard ratio [HR], 0.86;
P ¼.13), but NovoTTF monotherapy resulted
in significantly fewer severe adverse events (6%
v 16%; P ¼ .022) and a higher quality of life.15
Furthermore, unlike chemotherapies, TTFields are a
physical modality of treatment without a half-life
(unlike biochemical therapy) and therefore they
need to be continuously applied for maximal
effect.16 A post hoc analysis of the OS data on the
modified ITT (mITT) population, corrected for the
number of patients in the NovoTTF Therapy arm
who failed to receive at least one full treatment
course (see Kanner et al in this supplement), dem-
onstrated significantly longer median OS with
NovoTTF Therapy compared with chemotherapy,
7.7 versus 5.9 months, respectively (HR, 0.69; 95%
confidence interval [CI], 0.52–0.91; P ¼ .0093).
Additional analyses performed by Kanner et al also
linked higher NovoTTF Therapy compliance with
longer OS. Recently, there have been reports of a
limited but notable number of patients with recur-
rent GBM treated with NovoTTF Therapy in the
phase III trial17 and in an earlier pilot study12,18 who
experienced durable tumor responses with long-
term survival, some 10 years in duration until today.
Identifying such patients, as well as characterizing
their tumor response pattern, would help the future
selection of patients likely to receive particularly
benefit from NovoTTF Therapy. Therefore, the pur-
pose of the current analysis was to define the
response pattern in patients who exhibited objective
tumor responses to NovoTTF Therapy in these two
studies and to better evaluate their efficacy out-
comes in the context of kinetic modeling exploring
response to TTFields. In addition, the present study
examined baseline characteristics linked with higher
probability of response to NovoTTF Therapy, and
further explored the relationship between compli-
ance and efficacy outcomes. All analyses were
restricted to patients with recurrent GBM who
received NovoTTF Therapy alone (as monotherapy),and did not include patient responders from the
same pilot study who had newly diagnosed GBM
treated by NovoTTF Therapy with temozolomide.12METHODS
Clinical Trial Conduct and Analysis
In both the pilot and phase III trials, patients 18
years old or older with histologically confirmed GBM
(World Health Organization grade IV astrocytoma)
were eligible after radiologically confirmed disease
progression according to the Macdonald criteria.19
Patients had Karnofsky performance status (KPS)
ofZ70% and adequate hematologic, renal, and he-
patic function: absolute neutrophil count,Z1,000/
μL; hemoglobin,Z100 g/L; platelet count,
Z100,000/μL; serum creatinine level,r1.7 mg/dL
(o150 mmol/L); total serum bilirubin level,r upper
limit of normal; and liver function values,o3 times
upper limit of normal. Prior therapy must have
included radiotherapy (with and without concomitant
and/or adjuvant temozolomide). There was no limit
on number or type of prior therapies or recurrences.
Patients with infratentorial tumor were excluded, as
were patients with implanted electronic medical
devices (eg, pacemaker, programmable ventriculo-
peritoneal shunt). All patients provided written
informed consent, and the studies were approved
by the institutional review boards or ethics commit-
tees of all participating centers.
In the pilot trial, a total of 10 patients with
recurrent GBM were accrued and treated with
NovoTTF monotherapy without concurrent chemo-
therapy. In the phase III trial, 237 patients were
randomized at a 1:1 ratio to receive either NovoTTF
monotherapy or the best available chemotherapy
according to the local physician’s choice. Random-
ization was performed using random block sizes and
was stratified by center and according to whether
patients underwent surgery for their latest recur-
rence prior to trial entry. Assigned treatment had to
start within 1 week of randomization and was to be
continued until disease progression or intolerance.
For patient receiving NovoTTF Therapy in either
study, four transducer arrays were placed on the
shaved scalp and connected to a portable, battery- or
power supply–operated device. Treatment parame-
ters were preset to generate alternating electric
fields at a frequency of 200 kHz. This frequency is
associated with an electric field intensity distribution
across the entire supratentorial brain exceeding
0.7 V/cm. Thus, there were no electrical adjustments
required. Patients were trained to operate the device
and then continued treatment at home. Treatment
was continuous while patients were maintaining
normal daily activity. Transducer arrays were
J. Vymazal and E.T. WongS16replaced by the patients, their caregivers, or device
support specialists once or twice per week.
Although uninterrupted treatment was recom-
mended, patients were allowed to take treatment
breaks of up to 1 hour twice per day for personal
hygiene needs (eg, shower) or when severe scalp
irritation was observed. In addition, patients were
allowed to take 2 to 3 days off from treatment at the
end of each 4 weeks of treatment.
Follow-up was once a month and included labo-
ratory tests. MRI was repeated every month in the
pilot trial and every two months in the phase III trial
until disease progression, and then according to
local practice. Tumor response and progression
were determined by blinded central radiology
review, according to Macdonald criteria.19 MRI was
performed in at least two planes and included
T1- and T2-weighted sequences. T1-weighted
sequences were repeated after administration of
contrast agent. Fluid-attenuated inversion recovery
(FLAIR) and diffusion-weighted imaging studies were
not mandated in either study and were performed
according to local practice.
In the present analysis, all NovoTTF Therapy
scans from both studies were reviewed by a neuro-
radiologist (J.V.). Tumors were measured in two
dimensions based on T1 sequences with contrast
enhancement. T2, FLAIR, and diffusion-weighted
imaging sequences were assessed qualitatively. Time
to response, response duration, and OS in respond-
ers were calculated using the Kaplan-Meier method.
Correlations between response times and OS were
based on Pearson linear correlation.
Compliance Measures
The NovoTTF-100A device exerts its therapeutic
effect by physically disrupting tumor cells during
mitosis. Therefore, this treatment does not have a
half-life and is active only when the system is
delivering TTFields to the patient. In both trials, a
monthly compliance assessment was performed for
each patient by downloading an internal log file that
captures device “on” time. Patient compliance was
calculated as the average percentage of each day the
system was delivering fields out of each 24-hour
period. We hypothesized that compliance with treat-
ment would correlate with patient response and
survival, and tested our hypothesis by using the
Pearson linear correlation.
Compartmental Tumor Growth Model
A kinetic model of tumor volume changes under
NovoTTF Therapy versus in the absence of this
therapy was developed to help us better understand
the response pattern in our patients. Like other
published models,20–24 our model assumes thatchanges in tumor volume and size, for any given
time interval, are determined by the number of
tumor cells in the dormant or latent (L) state, cells
that leave the dormant state to enter mitosis and are
replicating (R), cells that die (D) within this time
interval, and cells that are cleared (C) from the
tumor microenvironment. It is assumed that the
volume of the individual cells in all states is constant
and that there are no significant tumor volume
changes caused by edema or other stromal changes.
The cell division cycle time for GBM is on the order
of 24 to 72 hours25 and is assumed to be constant in
the kinetic model. After division, a prespecified
fraction of the cells continue to the next cycle,
while others return to the dormant state (as
expressed by the mitotic index). Because GBM
frequently has a necrotic center, and the most
actively proliferating tumor cells are located periph-
eral to the center,26 we made a corresponding
adjustment in the model to closely approximate
the biological behavior of the tumor in a patient.
This constitutes a major difference between our
model and the previously published models. There-
fore, we modeled the replicating cells and the
clearance of dead cells to a vascular outer layer of
a constant width such that the volume of this layer,
relative to the entire tumor volume, decreases as the
tumor grows. In contrast, natural cell death occurs
only within the avascular core of the tumor such that
the number of cells undergoing natural death
increases with tumor volume. Replicating cell death
also occurs at rates that are affected by NovoTTF
Therapy.
For us to solve this model mathematically, the
minimal cell division cycle time (1 day) was taken as
the elementary time interval and served as the basic
iteration time. The need for an iterative rather than
analytical solution arises from the fact that the
system is not at equilibrium or even steady-state.
The number of dormant, dividing, and dead cells in
the tumor at each time point was summed and used
to represent the actual tumor volume at any time t.
Similar to first-order chemical kinetics, at any given
time the number of cells leaving a compartment is the
multiple of the rate constant and the number of cells
in the compartment. The model consists of 4 func-
tional compartments that are in constant dynamic
interaction. Dormant or latent (L) cells are in a
reversible transition with the dividing or replicating
(R) cells, with respective rate constants of k1 and k2.
The rate constants are balanced to keep the constit-
uents of the two compartments at a fixed ratio
consistent with the histologically determined fraction
of dividing cells in GBM tumors.27
Tumor cells are assumed to die or move to the
third compartment through two mechanisms. The
first is apoptosis, which mainly depends on nutrient
Figure 1. (A) Scheme representing the different compartments in the model and the rate constants associated with the
interactions between them. [L] ¼ Latent/Nondividing cells; [R] ¼ Replicating/Dividing cells; [D] ¼ Dead cells; [C] ¼ Cells
cleared from tumor by physiological mechanisms. TTFields were modeled as effecting K3. (B) Results of kinetic model
simulation. Relative changes in size of compartments of a tumor. Volume changes during the initial 9 months of NovoTTF
Therapy are characterized by growth of tumor volume in the initial month, with a maximum near 1 month followed by a
gradual decline. A reduction of tumor volume to 35% is observed at about 6.8 months, and this is equivalent to a 50%
decrease in bi-dimensional tumor measurement or partial response according to the Macdonald or RANO criteria.
Nondividing cells compartment (black); Dividing cells (green); Dead cells (blue); Total tumor volume (red); Vertical
dashed line ¼ peak tumor volume and time of tumor growth reversal (28 days).
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model, a single death rate constant (k4) was chosen.
The second mechanism is the rate of killing replicat-
ing (R) cells by NovoTTF Therapy, which is repre-
sented by a rate constant k3. The dead cells are
removed from the vascular layer of the tumor (at
least in part via phagocytosis28) by transferring them
into a virtual fourth compartment with a rate con-
stant k5 (Figure 1).
Assuming the tumor to be a perfect sphere with a
radius r, we limited cell replication and clearance to
a vascular circumferential layer of a constant width
Δr, while natural cell death is limited to the avascular
core with a radius of r – Δr. Thus, the apparent
kinetic constants k1 and k5 decrease as tumor volume
increases and k4 increases. This can be represented
mathematically as:
k1¼
ðr3ðrΔrÞ3Þ
r3
Uk01 k5¼
ðr3ðrΔrÞ3Þ
r3
Uk05
k4¼1
ðr3ðrΔrÞ3Þ
r3
 !
Uk04
To solve the model by iteration, these equations
were used:
R tð Þ¼RR n R t1ð Þ ð1Þ
R tþ1ð Þ¼R tð Þ–k3 n R tð Þ–k2 n R tð Þþk1 n L tð Þ ð2ÞL tþ1ð Þ¼L tð Þ–k1 n L tð Þ–k4 n L tð Þþk2 n R tð Þ ð3Þ
D tþ1ð Þ¼D tð Þþk3 n R tð Þþk4 n L tð Þ–k5 n D tð Þ ð4Þ
C tþ1ð Þ¼C tð Þþk5 n D tð Þ ð5Þ
Tumor Volume tð Þ¼L tð ÞþR tð ÞþD tð Þ ð6Þ
r tð Þ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
3
4Uπ UTumorVolumeðtÞ
3
r
ð7Þ
RR ¼ replication rate.RESULTS
Patient Characteristics and Tumor Responses
In this analysis, we examined a total of 130 patients
with recurrent GBM receiving NovoTTF Therapy as
monotherapy: 10 from the pilot study and 120 from
the phase III trial. In the pilot study, a 20% radiologic
response rate was reported (2 of 10 patients); in the
phase III trial, a 14% radiologic response rate was
reported (14 of 100). Thus, across both trials, a total of
16 responders (of which four had durable complete
responses) were reported out of the 110 patients with
baseline and at least one follow-up MRI (15% response
rate, 4% complete response rate). Responders to
NovoTTF Therapy had similar baseline characteristics
as the rest of the population in the two clinical trials
Table 1. Baseline Characteristics for Recurrent GBM Patients Treated With NovoTTF Therapy in the
Phase III and Pilot Studies and for Responders Across the Two Studies
Characteristic
Phase III NovoTTF
Therapy Patients
(n ¼ 120)
Pilot Trial NovoTTF
Therapy Patients
(n ¼ 10)
Responders to
NovoTTF Therapy
(n ¼ 16)
Age, years Median (range) 54 (24–80) 53 (28–68) 53.5 (36–75)
KPS, median (range) 80 (50–100) 90 (70–100) 90 (70–100)
Gender, % male 77% 70% 88%
Tumor area, cm2 Median (range) 14.4 (0.7–64.3) NA 10.0 (1.3–24.9)
Prior bevacizumab (%) 19% 0% 6%
Prior low grade (%) 8% 10% 31%
Prior lines of therapy Median
(range)
2 (1–5) 1 (1–3) 2 (1–3)
Patients at ﬁrst recurrence, % 9% 50% 19%
RT/TMZ at initial diagnosis, % 83% 80% 100%
TMZ cycles Median (range) 4 (0–19) NA 5 (0–12)
Abbreviations: KPS, Karnofsky performance status; RT, radiotherapy; TMZ, temozolomide.
J. Vymazal and E.T. WongS18(Table 1). Some of the baseline prognostic character-
istics appeared more favorable in responders than
nonresponders, including higher KPS (90 v 80), fewer
prior bevacizumab treatments (6% v 19%), more
patients with secondary GBM that were transformed
from prior low-grade gliomas (31% v 8%), and smaller
median tumor size (10.0 cm2 v 14.4 cm2). These
differences were not statistically significant in compar-
ison with the general study populations (multivariate
analysis of variance, P4.05). As both trials included
only patients with recurrent GBM, biopsy at recur-
rence was not required, and genetic analysis of tumor
tissue was not routinely performed.
Response Patterns
Figures 2 to 4 show exemplary T1-weighted MRI
scans of responders to NovoTTF Therapy. With
respect to response patterns, the most prominentFigure 2. Exemplary T1-weighted images after contrast agent
astrocytoma, which transformed to glioblastoma (based on
chemoradiotherapy and adjuvant temozolomide (3 courses) a
12 months) and remained stable for an additional 20 months ofindings were that tumor responses to NovoTTF
Therapy developed relatively slowly but in most
cases were durable. As seen in Figure 5, the median
time to objective radiographic response in the 16
patients was 5.2 months (95% CI, 3.2–7.6 months).
The median response duration in these patients was
12.9 months (95% CI, 2.1–not available [NA]
months). Twelve of the 16 responders (75%) had
durable responses lasting longer than 12 months.
Also, response duration was highly correlated with
OS (r2 ¼ .97, Po.0001). Median OS for responders
was 26.5 months (95% CI, 17.1–NA months).
Delayed Response
Of note, for seven of the 16 responders (44%), MRI
showed the initial tumor growth. An exemplary MRI
of such a delayed responder can be found in Figure 6.
Median time to reversal of tumor growth in delayedadministration of a 48-year-old male with prior grade II
tissue biopsy). The subject progressed after receiving
nd subsequently responded to NovoTTF Therapy (PR at
n TTFields.
Figure 3. Exemplary T1 images after contrast agent administration of a 51-year-old male with primary GBM who
recurred 6 months after chemo-radiation with temozolomide. The patient never underwent surgery (biopsy only). He had
a very gradual response, reaching a 50% reduction in tumor size after 10 months on NovoTTF Therapy. He remained
stable for an additional 2 months on NovoTTF Therapy.
Response patterns of recurrent glioblastomas treated with TTFields S19responders was four months (95% CI, 2.3–7.4
months). The initial tumor growth was accompanied
by an increase in T2-weighted and/or FLAIR signal in
five of these seven delayed responders (71%; see
Figure 6). Diffusion-weighted imaging in three of the
seven delayed responders did not demonstrate a
diffusion-weighted signal increase in the first 4 months
after treatment initiation. The averaged maximalFigure 4. Exemplary T1-weighted images after contrast agent
who recurred for the third time after receiving chemoradiothera
irinotecan (3 months) and erlotinib with sorafenib (one cycle).
after 4 months of treatment and remained stable for an additiotumor area over time compared to baseline in the
delayed responders is shown in Figure 7.Compliance Versus Response and Survival
Compliance and Kaplan-Meier estimates of
median OS were compared in patients with com-
plete responses, partial responses, stable disease,administration of a 55-year-old male with primary GBM
py, adjuvant temozolomide (2 cycles), bevacizumab with
The subject had a partial response to NovoTTF Therapy
nal 8 months while on NovoTTF Therapy.
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Figure 5. Kaplan Meier curves of the time to radiologi-
cal response according to Macdonald criteria (blue line),
response duration (red line), and overall survival (black
line) of the 16 responders from the two clinical trials.
J. Vymazal and E.T. WongS20and progressive disease. As seen in Table 2, an
increase in compliance was associated with better
response to treatment and longer OS. The extent of
response from treatment (PRþCR, SD, PD, and NA)
was also significantly dependent on compliance
(ANOVA Po.001, Figure 8).
Kinetic Modeling of Delayed Responses
Tumor growth kinetics were studied by means
of a multicompartment model. The model reflects
the balance between the changes occurring in the
number of dormant and replicating cells, on the one
hand, and cells that die “naturally” or as a result of
TTFields treatment (Figure 1A). The rate constants
when cells shift from one compartment to the other,
and the replication rate and other parameters used in
the numerical solution, were derived from published
data (Table 3). The model predicts that, when GBM
tumors are continuously exposed to TTFields, they
will cease to increase in size and begin to shrink only
after 4 weeks of continuous TTFields exposure
(Figure 1B). This behavior is consistent with the
data presented above for the seven patients with
delayed response to NovoTTF Therapy
(Figure 7).12,25,27,29–31DISCUSSION
NovoTTF Therapy is new antimitotic treatment
that kills or arrests the growth of recurrent GBM
tumors by delivering TTFields that disrupt mitotic
spindle formation during metaphase to anaphasetransition and by potentiating aberrant dielectropho-
retic movement of intracellular macromolecules and
organelles during anaphase and telophase, resulting
in chromosome missegregation and cell death.16,32
Because of this unique mechanism of action,
NovoTTF Therapy is selective for dividing cells and
requires continuous application for maximal benefit.
We report here that 15% of patients with recur-
rent GBM tumors responded to NovoTTF Therapy
with a complete or partial radiological response, and
that these responses typically developed slowly
(median time to response, 5.2 months) and are in
most cases durable (median duration, 12.9 months).
By way of comparison, only 9.6% of patients treated
with best active chemotherapy in the phase III trial
exhibited an objective radiological response (seven
partial responses v 3 complete and 11 partial
responses in the NovoTTF Therapy cohort).15 More-
over, a response assessment of the phase III trial data
by Wong et al showed that response duration was
highly correlated with OS in the NovoTTF Therapy
cohort (r2¼0.92, Po.0001), but not in the best
active chemotherapy cohort (r2¼0.06, P¼.6226).33
The current analyses also demonstrated that roughly
half (44%) of the GBM tumors responding to
NovoTTF Therapy initially exhibit growth on MRI,
before reversing and shrinking in size 2 to 7 months
(median, 4 months) later with continuous therapy.
Therefore, these results suggest that NovoTTF Ther-
apy effects a response slowly, and when it occurs,
the response is often durable.
To better characterize our observation on tumor
shrinkage induced by NovoTTF Therapy, we con-
structed a kinetic model based on the states of cells,
between latency and replication as well as their
progression to death and clearance, within the
tumor microenvironment. Using rate constants
obtained from published literature, we were able
to construct a tumor volume kinetics curve that
showed a doubling of the baseline tumor volume at
4 weeks before a reduction approximating a two-
dimensional reduction in the tumor measurement
near 7 months. This kinetics closely approximate our
observed time to GBM shrinkage in patients as
shown in Figure 7, in which there was an initial
increase in tumor size that constitutes progressive
disease, and tumor shrinkage that qualifies for a
partial response did not occur until48 months after
NovoTTF Therapy. Therefore, these results from the
kinetics model help to better characterize tumor
response to NovoTTF Therapy, which predicts GBM
tumors will cease to grow and start to shrink only
after at least several weeks of continuous TTFields
exposure. However, objective tumor response may
not occur until at least 7 to 8 months later.
The current study provides an association between
patient outcomes and treatment compliance with
Figure 6. Exemplary T1-weighted images after contrast agent administration with their corresponding FLAIR and Diffusion
MRI scans of a heavily pretreated 48-year-old man with secondary GBM. The patient underwent three debulking surgeries,
chemo-radiation with temozolomide, and gamma knife boost. The patient’s tumor showed heterozygous deletions of 1p
and 19q and was MGMT promoter methylated. The patient was treated with NovoTTF Therapy for 28 months until
radiological response was achieved and has been on treatment since (for 45 months so far). Notably, the patient’s tumor
grew for the ﬁrst 8 months on NovoTTF Therapy and only then started to decrease in size. Additional MRI sequences show
that while the tumor was growing initially, this was accompanied by an increase in FLAIR signal, but not in diffusion signal.
Response patterns of recurrent glioblastomas treated with TTFields S21NovoTTF Therapy. Our data show that the likelihood
of a radiological response increases with increased
compliance with NovoTTF Therapy, ie, the closer theFigure 7. Time course of normalized tumor size in the sev
presented as average tumor area  standard deviation normalizpatient comes to “continuous” application of TTFields,
and that responders have a longer median OS than
nonresponders (24.7 months for responders v 7.6 anden delayed responders to NovoTTF Therapy. Data are
ed to baseline (pretreatment) tumor area.
Table 2. Response, Median Overall Survival, and Compliance With NovoTTF Therapy in the Phase
III Trial
Comparison to Responders (PRþCR)
Response
Median
OS (mo)
Average Compliance
(average % per 24 h) n
Hazard Ratio
(95% CI)
Log Rank
P Value
PR and CR 24.7 92 14
SD 7.6 85 34 0.28 (0.14–0.58) .0006
PD 5.5 79 59 0.24 (0.14–0.42) o.0001
No follow-up MRI (NA) 2.4 60 13 0.08 (0.02–0.26) o.0001
All patients 6.6 83 120
Abbreviations: OS, overall survival; CI, conﬁdence interval; PR, partial response; CR, complete response; SD, stable disease;
PD, progressive disease.
J. Vymazal and E.T. WongS225.5 months for patients with stable disease or pro-
gressive disease, respectively). These compliance data
are consistent with those reported by Kanner and
colleagues (corresponding article in this supplement),
which show significantly longer median OS in
NovoTTF Therapy-treated recurrent GBM patients
with a maximal monthly compliance rate ofZ75%
versuso75% (7.7 v 4.5 months, P¼.042). Kanner
et al also report a significant trend for improved
median OS with stepwise increases in compliance
(5.8, 6.0, and 7.7 months foro60%, 60%–79%, and
80%–99% compliance, respectively; P¼.039).
A number of recurrent GBM patients with delayed
and durable responses from NovoTTF Therapy have
been described.17,18 Villano et al recently presented
in detail the case of a 48-year-old man with recurrent
GBM who received NovoTTF Therapy during the
phase III trial. His tumor response pattern was
characterized by a slow but continuous increase in
tumor size over 10 months, followed by a period of
stabilization and then partial response that lasted for
another 4 years. Notably, this patient survived more
than 6 years from the time of initiation of NovoTTFFigure 8. ANOVA analysis of the extent of response is signiﬁca
PD, and NA (Po.001).Therapy.17 Similarly, Rulseh et al also reported
delayed responses in two patients that occurred
5 and 7 months from NovoTTF Therapy initiation,
and they lived 6 and 5 years thereafter, respec-
tively.18 These two patients are still alive, currently
10 years after their initial diagnosis. Taken together,
these cases suggest that certain patients respond
to NovoTTF Therapy only after a delay, but once
they respond, the response is durable.
Another important question that remains to be
answered is if patients who eventually respond to
NovoTTF Therapy can be identified by their clinical or
tumor characteristics. Kanner et al performed a num-
ber of post hoc analyses of the phase III trial data,
identifying prior failure of bevacizumab therapy, prior
low-grade glioma, and tumor sizeZ18 cm2 as poten-
tially relevant variables for further study. Examination
of baseline patient characteristics in the present study
highlighted a number of variables possibly linked with
tumor response (and, by extension, OS) that might be
worthy of further study, including higher KPS, prior
bevacizumab therapy, and prior low-grade glioma.
Lower cumulative dexamethasone dose has also beenntly different among the four major groups, PRþCR, SD,
Table 3. Comparison of Literature and Model Kinetic Parameters
Parameter Model Literature Reference
RR  1.29 / d  1–2 / d Hoshino, 199227
K1 0.28 / d 0.18–0.40 Chiesa-Vottero et al, 2003
28
K2 0.48 / d Calculated Calculated to maintain R/L ¼ K1
K3 0.50 / d 0.40–0.60 Kirson et al, 2007
14
K4 0.022 / d 0.034  0.022 Mizoguchi et al, 2000
32
K5 0.007 / d (0.016 – 0.26) / d Gong et al, 1999
31
Δr 0.20 Estimated Chen et al, 200630
Abbreviations: RR, replication rate; K1 and K2, forward and reverse rate constants of cells between latency and replication; K3, rate
constant for killing replicating cells by TTFields; K4, single rate constant for killing replicating cells; K5, rate constant for removal of dead
cells from vascular layer of tumor; Δr, wide of vascular circumferential layer where tumor cell replication and clearance occur.
Response patterns of recurrent glioblastomas treated with TTFields S23linked with response to NovoTTF Therapy in recurrent
GBM.33 Therefore, by identifying patients for whom
NovoTTF Therapy might provide long-term survival
benefit would be potential means of providing them
personalized therapy. In addition, compliance has
been linked not only in this study but also in the ones
by Kanner et al and Mrugala et al (current supple-
ment) with improved median OS. The present study
also associated NovoTTF Therapy compliance with
increased likelihood of achieving a tumor response,
and tumor response—and particularly response dura-
tion—was correlated with OS. Since compliance and
dexamethasone are modifiable variables, these hypoth-
eses can be readily tested in future clinical trials.
In summary, NovoTTF Therapy represents a novel
treatment option for patients with recurrent GBM.
About 15% of patients experience slowly developing
but durable tumor responses, a number of which
have now been linked with survival of 7 years or
longer. Tumor responses develop gradually and
initial tumor growth may even be observed in
eventual responders to NovoTTF Therapy. In addi-
tion, compliance has been linked with increased
likelihood of tumor response and improved OS.
Taken together, these results suggest physicians
should impress the importance of compliance upon
their patients receiving NovoTTF Therapy, and
should not rely solely on early radiographic changes
as a reason for discontinuing treatment.Acknowledgments
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